Extracorporeal Blood Purification Supported by VA-ECMO in Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with high death rates despite advances in revascularization and temporary mechanical circulatory support.Beyond clinical staging tools such as the Society for Cardiovascular Angiography and Interventions classification, biomarker panels are increasingly being explored to improve risk prediction.A central question is whether these biomarkers can also serve as treatment targets.In CS, inflammation is present but generally less intense than in septic shock, and about one-third of patients develop infections that further worsen outcomes.Low cardiac output and impaired blood flow to the gut can damage the intestinal barrier, allowing lipopolysaccharide (LPS) to enter the circulation and exacerbate vascular tone abnormalities and cardiac dysfunction.Venoarterial extracorporeal membrane oxygenation (VA-ECMO) adds additional inflammatory stimuli through blood-circuit interactions, complement and coagulation activation, hemolysis, and cytokine release.In sepsis, several blood purification devices have been studied.The oXiris membrane combines renal replacement therapy with cytokine and endotoxin removal; polymyxin-B direct hemoperfusion selectively binds endotoxin; and CytoSorb removes a broad spectrum of mid-sized molecules, including cytokines.Although these devices effectively reduce inflammatory mediators, randomized trials in sepsis have not consistently demonstrated improvements in survival or organ recovery, and current guidelines recommend their use only in research settings.Similarly, recent randomized trials in CS patients supported with VA-ECMO have shown reductions in cytokines or LPS but no improvement in clinical outcomes, such as ECMO weaning, organ function, or survival.Accordingly, further research is needed to determine which patients with CS may benefit from blood purification, particularly in the setting of mechanical circulatory support, and to define how such therapy should be optimally applied.